CoChat

Reconsidering pluripotency tests: Do we still need teratoma assays?

Open access
Buta, Christiane, David, Robert, Dressel, Ralf, Emgård, Mia, Fuchs, Christiane, Gross, Ulrike, Healy, Lyn, Hescheler, Jürgen, Kolar, Roman, Martin, Ulrich, Mikkers, Harald, Müller, Franz-Josef, Schneider, Rebekka K., Seiler, Andrea E.M., Spielmann, Horst, Weitzer, Georg · 2013 · Stem Cell Research
Cited by 101

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The induction of teratoma in mice by the transplantation of stem cells into extra-uterine sites has been used as a read-out for cellular pluripotency since the initial description of this phenomenon in 1954. Since then, the teratoma assay has remained the assay of choice to demonstrate pluripotency, gaining prominence during the recent hype surrounding human stem cell research. However, the scientific significance of the teratoma assay has been debated due to the fact that transplanted cells are exposed to a non-physiological environment. Since many mice are used for a result that is heavily questioned, it is time to reconsider the teratoma assay from an ethical point of view. Candidate alternatives to the teratoma assay comprise the directed differentiation of pluripotent stem cells into organotypic cells, differentiation of cells in embryoid bodies, the analysis of pluripotency-associated biomarkers with high correlation to the teratoma forming potential of stem cells, predictive epigenetic footprints, or a combination of these technologies. Each of these assays is capable of addressing one or more aspects of pluripotency, however it is essential that these assays are validated to provide an accepted robust, reproducible alternative. In particular, the rapidly expanding number of human induced pluripotent stem cell lines, requires the development of simple, affordable standardized in vitro and in silico assays to reduce the number of animal experiments performed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.scr.2013.03.001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Regulatory networks define phenotypic classes of human stem cell lines

    Müller, F.-J., Laurent, L. C., Kostka, D., Ulitsky, I., Williams, R., Lu, C., Park, I.-H., Rao, M. S., Shamir, R., Schwartz, P. H., et al. (2008) · Nature · doi:10.1038/nature07213 · Cited by 343 · cited 5×

    “Yet, teratocarcinoma cell lines, genetically abnormal hESC and iPSC cultures, as well as epigentically irregular, e.g. partially reprogrammed cell lines, do frequently express the same markers at comparable levels (Chan et al., 2009; Müller et al., 2008).”
    InfluentialSelf-citation

Show all 1 references

Cited by

See all 101

Metadata

Authors
Buta, C., David, R., Dressel, R., Emgård, M., Fuchs, C., Gross, U., Healy, L., Hescheler, J., Kolar, R., Martin, U., Mikkers, H., Müller, F.-J., Schneider, R. K., Seiler, A. E. M., Spielmann, H., & Weitzer, G.
Venue
Stem Cell Research
Publisher
Elsevier BV
Published
2013-07
Volume
11
Issue
1
Pages
552-562
ISSN
1873-5061 (ISSN-L)
OpenAlex
W1977751194
Cited by
101
References
1
FWCI
4.30
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reconsidering pluripotency tests: Do we still need teratoma assays? https://app.cochat.ai/papers/10.1016/j.scr.2013.03.001
The paper
Buta, C., David, R., Dressel, R., Emgård, M., Fuchs, C., Gross, U., Healy, L., Hescheler, J., Kolar, R., Martin, U., Mikkers, H., Müller, F.-J., Schneider, R. K., Seiler, A. E. M., Spielmann, H., & Weitzer, G. (2013). Reconsidering pluripotency tests: Do we still need teratoma assays? Stem Cell Research. https://doi.org/10.1016/j.scr.2013.03.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.